Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity

Journal of Crohn's and Colitis

Volumn 7, Issue 12, 2013, Pages

  Strid, Hans ^a   Simrén, Magnus ^a   Lasson, Anders ^a,b   Isaksson, Stefan ^a   Stridsberg, Mats ^c   Öhman, Lena ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Section of Rheumatology   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chromogranin; IBD; Secretogranin; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; C REACTIVE PROTEIN; CALGRANULIN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; CORTICOSTEROID; MERCAPTOPURINE; SECRETOGRANIN II; SECRETOGRANIN III; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FECES ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; ULCERATIVE COLITIS;

CHROMOGRANIN; IBD; SECRETOGRANIN; ULCERATIVE COLITIS;

ADULT; C-REACTIVE PROTEIN; CHROMOGRANIN A; CHROMOGRANIN B; CHROMOGRANINS; COLITIS, ULCERATIVE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PURINES; RECURRENCE; REMISSION INDUCTION; SECRETOGRANIN II; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84887608877     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.04.019     Document Type: Article

References (20)

1. Chanat E., Huttner W.B. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991, 115:1505-1519.
2. Shooshtarizadeh P., Zhang D., Chich J.F., Gasnier C., Schneider F., Haikel Y., et al. The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul Pept 2010, 165:102-110.
3. El-Salhy M., Danielsson A., Stenling R., Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997, 242:413-419.
4. El-Salhy M., Gundersen D., Hatlebakk J.G., Hausken T. Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci 2012 Dec, 57(12):3154-3159.
5. Granberg D., Stridsberg M., Seensalu R., Eriksson B., Lundqvist G., Oberg K., et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999, 84:2712-2717.
6. Sciola V., Massironi S., Conte D., Caprioli F., Ferrero S., Ciafardini C., et al. Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:867-871.
7. Sidhu R., McAlindon M.E., Leeds J.S., Skilling J., Sanders D.S. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009, 18:23-26.
8. Lawrence B., Gustafsson B.I., Kidd M., Pavel M., Svejda B., Modlin I.M. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40:111-134.
9. Helle K.B. Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions. Regul Pept 2010 Nov 30, 165(1):45-51.
10. Bartolomucci A., Pasinetti G.M., Salton S.R. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 2010, 170:289-297.
11. Öhman L., Stridsberg M., Isaksson S., Jerlstad P., Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?. Am J Gastroenterol 2012, 107:440-447.
12. Öhman L., Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010, 7:163-173.
13. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
14. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
15. Stridsberg M., Eriksson B., Janson E.T. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008, 148:95-98.
16. Stridsberg M., Oberg K., Li Q., Engstrom U., Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995, 144:49-59.
17. Nobels F.R., Kwekkeboom D.J., Bouillon R., Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998, 28:431-440.
18. Moran G.W., Pennock J., McLaughlin J.T. Enteroendocrine cells in terminal ileal Crohn's disease. J Crohns Colitis 2012, 6:871-880.
19. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149.
20. Bischoff S.C., Wedemeyer J., Herrmann A., Meier P.N., Trautwein C., Cetin Y., et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996, 28:1-13.